5-Fluorouracil versus 5-fluorouracil plus α-interferon as treatment of metastatic colorectal carcinoma. A randomized study

Annals of Oncology

Volumn 7, Issue 6, 1996, Pages 575-579

  Dufour, P ^a   Husseini, F ^b   Dreyfus, B ^c   Cure, H ^d   Martin, C ^e   Prevost, G ^f   Olivier, J P ^g   Dumas, F ^h   Duclos, B ^a   Olivares, R ⁱ   Leszier, A ⁱ   Bergerat, J P ^a   Audhuy, B ^b   Thill, L ⁱ   Oberling, F ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b Pasteur Hospital   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d CENTRE JEAN PERRIN   (France)

^e Centre Hospitalier de la Region d'Annecy   (France)

^f CENTRE HOSPITALIER DE MULHOUSE   (France)

^g LIMOGES UNIVERSITY HOSPITAL   (France)

^h HAUT LÉVÊQUE HOSPITAL   (France)

ⁱ Produits Roche   (France)

Author keywords

5 FU; Colorectal carcinoma; Metastatic; interferon

Indexed keywords

ALPHA2A INTERFERON; FLUOROURACIL;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 9444222464     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010673     Document Type: Article

References (22)

1. Wadler S, Schwartz EL, Goldman M et al. Fluorouracil and recombinant alpha-2a interferon: An active regimen against advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1769-75.
2. Bruckner HW, Motwani BT. Chemotherapy of advanced cancer of the colon and rectum. Semin Oncol 1991; 18: 443-61.
3. Houghton JA, Cheshire PJ, Morton CL et al. Potentiation of 5-fluorouracil-leucovorin activity by 2a-interferon in colon adenocarcinoma xenografts. Clin Cancer Res 1995; 1: 33-40.
4. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review. Cancer Res 1990; 50: 3473-786.
5. Kirkwood JM, Ernstoff MS. Interferons in the treatment of human cancer. J Clin Oncol 1984; 2: 336-52.
6. John WJ, Neefe JR, MacDonald JS et al. 5-Fluorouracil and interferon-α 2a in advanced colorectal carcinoma. Results of two treatment schedules. Cancer 1993; 72: 3191-5.
7. Pazdur R, Ajani JA, Patt YZ et al. Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma. Cancer 1993; 71: 1214-8.
8. Wadler S, Lembersky B, Atkins M et al. Phase II trial of fluorouracil and recombinant interferon alpha-2a in patients with advanced colorectal carcinoma: An eastern cooperative oncology group study. J Clin Oncol 1991; 9: 1806-10.
9. Huberman M, McClay E, Atkins M et al. Phase II trial of 5-fluorouracil (5-FU) and recombinant alpha-2a interferon in advanced colorectal cancer. Proc Am Soc Clin Oncol 1991; 10: 153 (Abstr 478).
10. Kemeny N, Younes A, Seiter K. Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity. Cancer 1990; 66: 2470-5.
11. Douillard JY, Leborgene J, Danielou JY et al. Phase II trial of 5-fluorouracil and recombinant a-interferon in metastatic previously untreated colorectal cancer. Proc Am Soc Clin Oncol 1991; 10: 139 (Abstr422).
12. Hansen RM, Ritch PS, Libnoch JA et al. Continuous 5-fluorouracil infusion and a-interferon in advanced cancers: A report of initial treatment results. Am J Med Sci 1991; 301: 246-9.
13. Raderer M, Scheithauer W. Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-α: An overview of clinical trials. Eur J Cancer 1995; 31 A: 1002-8.
14. York M, Greco FA, Einhorn L et al. A randomized phase III trial comparing 5-FU with or without interferon alfa-2a for advanced colorectal cancer. Proc Am Soc Clin Oncol 1993; 12: 200, (Abstr 590).
15. Hill M, Norman A, Cunningham D et al. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol 1995; 13: 1297-302.
16. Lokich JJ, Ahlgren JD, Gullo JJ et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A midatlantic oncology program study. J Clin Oncol 1989; 7: 425-32.
17. Ehrlichman C, Fines S, Wong. A randomized trial of fluorouracil with folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988; 6: 469-75.
18. Martoni A, Cricca A, Guaraldi M et al. Randomized clinical trial with a weekly regimen of 5-FU vs. 5-FU + intermediate-dose folinic acid in the treatment of advanced colorectal cancer. Ann Oncol 1992, 3: 87-8.
19. Advanced colorectal cancer meta-analysis project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
20. Hill M, Norman A, Cunningham D et al. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival and quality of life in advanced colorectal cancer. J Clin Oncol 1995; 13: 2317-23.
21. Corfu-A study group. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 1995; 13: 921-28.
22. Ragnhammar P, Blomgren H, Edler D et al. Different dose regimens of 5-fluorouracil and interferon-α in patients with metastatic colorectal carcinoma. Eur J Cancer 1995; 31 A: 315-20.